If you've been paying out of pocket for Wegovy or Zepbound — or you qualified for one but couldn't touch the price — this is the change you've been waiting for. Beginning July 1, 2026, the Medicare GLP-1 Bridge, a temporary demonstration program from the Centers for Medicare & Medicaid Services (CMS), gives eligible Medicare beneficiaries access to select GLP-1 weight-management medications for a flat $50 per monthly supply.
That's a genuinely big deal. Until now, Medicare drug plans were prohibited by law from covering medications prescribed solely for weight loss. The Bridge doesn't repeal that law — it steps around it, temporarily, as a demonstration program that runs through December 31, 2027.
As with everything Medicare, the details decide whether this actually helps you. Let's walk through them the way I would at my whiteboard.
What the GLP-1 Bridge covers
At launch, three products are included when prescribed for a weight-management indication (losing excess weight, or maintaining weight you've already lost):
- Wegovy (semaglutide) — all formulations
- Zepbound (tirzepatide) — the KwikPen formulation specifically
- Foundayo — all formulations
Two things to notice. First, the list is selective — this isn't blanket coverage of every GLP-1 on the market, and the covered list can change during the demonstration. Second, the indication matters: GLP-1s prescribed for type 2 diabetes (like Ozempic) were already covered under Part D the normal way. The Bridge exists specifically for the weight-management prescriptions Medicare used to exclude.
Who qualifies
You need two things: Medicare drug coverage (a standalone Part D plan or a Medicare Advantage plan that includes drug coverage) and clinical eligibility your prescriber attests to. The clinical criteria work in tiers:
| Your BMI | What else is required |
|---|---|
| 35 or higher | Nothing else — BMI alone qualifies you |
| 30 – 34.9 | Chronic kidney disease, uncontrolled high blood pressure, or heart failure with preserved ejection fraction |
| 27 or higher | Prediabetes (A1C of 5.7–6.4), a history of heart attack or stroke, or symptomatic blocked leg arteries (peripheral artery disease) |
Here's a detail that will matter to a lot of people: eligibility is based on your numbers when you first started GLP-1 therapy — not the day the Bridge claim is filed. If you started a GLP-1 in 2024 at a BMI of 37 and you've since worked your way down to 31, you can still qualify, as long as your prescriber can attest you met the threshold at initiation. The program doesn't punish you for the medication working.
What it costs — and the fine print
Eligible beneficiaries pay $50 for a monthly supply. Compared to list prices that have run over $1,000 a month out of pocket, that's transformative. But three pieces of fine print deserve your attention:
- The $50 doesn't count toward your Part D deductible or your annual out-of-pocket cap. Bridge spending lives outside your drug plan's math.
- Extra Help doesn't apply. If you receive the Part D Low-Income Subsidy, it cannot be used to reduce the $50 Bridge copay.
- The Bridge runs outside your Part D plan entirely. CMS uses a single central processor for prior authorization, claims, and pharmacy payment. Your plan's formulary and network rules don't decide Bridge coverage — which also means your plan can't be blamed, or credited, for it.
The part nobody should skip: it's temporary
The Bridge is a demonstration — a structured experiment. It starts July 1, 2026 and is currently set to end December 31, 2027. CMS has not committed to what happens afterward. It could become permanent coverage, change shape, or simply end.
That means anyone starting a GLP-1 under the Bridge should have a conversation with their prescriber about the exit ramp: what happens to your treatment plan if the subsidy disappears in 18 months? Starting a medication you can only afford temporarily is a decision worth making with open eyes — it's exactly the kind of trade-off I'd want you to understand before you commit, not after.
What Northern Nevada beneficiaries should do now:
1) If you think you qualify, talk to your prescriber — they attest to your clinical eligibility, including retroactively if you started GLP-1 therapy before the Bridge existed. 2) Confirm you're enrolled in Medicare drug coverage; the Bridge requires it even though it pays outside your plan. 3) If you're choosing or changing a Medicare plan this fall, don't pick a plan because of GLP-1 coverage promises — Bridge coverage follows you regardless of which Part D or Advantage plan you're on. Pick the plan that fits your doctors, pharmacies, and other prescriptions, the way you always should.
Where this fits in your bigger Medicare picture
The Bridge is a good reminder of something I tell clients in Carson City, Minden, Dayton, and everywhere in between: Medicare is not a set-it-and-forget-it purchase. Programs launch, formularies shift, networks change — every single year. That's why I re-check my clients' Medicare coverage every fall during the Annual Enrollment Period (October 15 – December 7), prescriptions included.
If you're not sure whether your current plan still fits — or you're turning 65 and building your coverage from scratch — a review costs you nothing. We'll look at your doctors, your drug list (GLP-1s included), and your budget, and I'll teach you how the moving parts fit together before you decide anything.
Quick answers
When does the Medicare GLP-1 Bridge program start and end?
The demonstration runs from July 1, 2026 through December 31, 2027. It is temporary — CMS has not committed to what happens after it ends, so it's wise to have a plan for both outcomes.
Which weight-loss medications does the Medicare GLP-1 Bridge cover?
At launch, the Bridge covers all formulations of Wegovy, all formulations of Foundayo, and the KwikPen formulation of Zepbound — when prescribed for a weight-management indication. The covered list can change during the demonstration.
How much do GLP-1s cost under the Bridge program?
Eligible beneficiaries pay $50 for a monthly supply. Note that the $50 does not count toward your Part D deductible or annual out-of-pocket cap, and Extra Help (the Low-Income Subsidy) does not apply to Bridge claims.
Who qualifies for the Medicare GLP-1 Bridge?
You must be enrolled in Medicare drug coverage and meet clinical criteria your prescriber attests to: generally a BMI of 35 or higher qualifies on its own; a BMI of 27 or higher can qualify with prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease; and a BMI of 30–34.9 can qualify with chronic kidney disease, uncontrolled high blood pressure, or heart failure with preserved ejection fraction. Eligibility is based on your numbers when you first started GLP-1 therapy, not today.
Does the GLP-1 Bridge go through my Part D plan?
No — the Bridge runs outside the normal Part D benefit. CMS uses a single central processor to handle prior authorization, claims, and pharmacy payment, so your plan's formulary and pharmacy network rules don't decide Bridge coverage.
This article is educational and reflects program details published by CMS as of July 2026; demonstration rules can change. It is not medical, financial, tax, or legal advice — talk to your prescriber about whether a GLP-1 is right for you, and verify current program details at Medicare.gov or 1-800-MEDICARE. Daniel J. Faiella is an independent licensed insurance agent and is not affiliated with or endorsed by the U.S. government, the federal Medicare program, or any government agency.